Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The subscription of shares by Whirlpool China is expected to strengthen the global collaboration and influence of the company, enhancing cooperation with the group [2] - The current dividend yield for WHR is 4.95%, indicating a favorable financial return [2] - Future growth is anticipated due to the company's ability to secure orders from Whirlpool Group, increased OEM releases in Japan and Southeast Asia, cost reduction and efficiency improvements after the acquisition of Galanz, and changes in competitive dynamics [2] Financial Projections - The company is projected to achieve net profits of 505 million, 616 million, and 743 million yuan for the years 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 150.5%, 21.8%, and 20.7% [2] - Revenue is expected to grow from 4,455 million yuan in 2025 to 6,454 million yuan in 2027, with corresponding growth rates of 22.1%, 21.1%, and 19.7% [3] - The latest diluted EPS is projected to increase from 0.66 yuan in 2025 to 0.97 yuan in 2027 [3] Financial Metrics - The company’s total revenue for 2023 is reported at 4,004 million yuan, with a projected decline of 6.1% year-on-year [3] - The net profit for 2023 is reported at 81 million yuan, with a significant year-on-year increase of 190.4% [3] - The return on equity (ROE) is expected to rise from 3.2% in 2023 to 29.9% in 2027 [3]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The proposed subscription of $30 million in common stock by Whirlpool China aims to strengthen global collaboration with the Whirlpool Group, enhancing its influence and deepening cooperation. The current dividend yield for WHR is 4.95%, indicating good financial returns [2] - The company is expected to benefit from increased orders from the Whirlpool Group, growth in OEM releases in Japan and Southeast Asia, cost reduction and efficiency improvements following the acquisition by Galanz, and changes in competitive dynamics within the industry. Future growth is anticipated [2] Financial Projections - Revenue is projected to grow from 4,004 million yuan in 2023 to 6,454 million yuan in 2027, with year-on-year growth rates of -6.1% in 2023, 22.1% in 2025, 21.1% in 2026, and 19.7% in 2027 [3] - Net profit attributable to the parent company is expected to increase from 81 million yuan in 2023 to 743 million yuan in 2027, with significant growth rates of 190.4% in 2024, 150.5% in 2025, 21.8% in 2026, and 20.7% in 2027 [3] - The latest diluted EPS is forecasted to rise from 0.11 yuan in 2023 to 0.97 yuan in 2027 [3] - The return on equity (ROE) is projected to improve from 3.2% in 2023 to 29.9% in 2027 [3] Valuation Metrics - The price-to-earnings (P/E) ratio is expected to decrease from 113.7 in 2023 to 12.4 in 2027, indicating a more attractive valuation over time [3] - The price-to-book (P/B) ratio is projected to remain relatively stable, ranging from 3.6 in 2023 to 3.7 in 2027 [3]

Core Viewpoint - Sovereign wealth funds and long-only investors have shown sufficient interest to purchase all shares offered in the Hong Kong listing of Lanke Technology, indicating strong demand for the stock which has been oversubscribed multiple times [1] Group 1 - Sovereign wealth funds and long-only investors typically invest in stocks expected to rise and do not engage in short selling [1] - The shares of Lanke Technology have received multiple times subscription, reflecting robust investor confidence [1]

（注：上述数据截止日为2026年01月27日。） 投资者可登录国投瑞银基金管理有限公司网站http://www.ubssdic.com，或拨打客户服务电话：400-880- 6868咨询相关信息。 特此公告。 登录新浪财经APP 搜索【信披】查看更多考评等级 国投瑞银基金管理有限公司（以下简称本公司）旗下基金参加了深圳麦格米特电气股份有限公司（以下 简称麦格米特，代码：002851.SZ）非公开发行股票的认购。麦格米特已发布《深圳麦格米特电气股份 有限公司向特定对象发行股票发行情况报告书》，根据中国证监会《公开募集证券投资基金信息披露管 理办法》《关于基金投资非公开发行股票等流通受限证券有关问题的通知》等有关规定，现将本公司旗 下基金投资麦格米特非公开发行股票的相关信息公告如下： ■ 4、本基金二级市场的交易价格，除了有基金份额净值波动的风险外，还会受到市场供求关系、系统性 风险、流动性风险等其他因素的影响，可能使投资者面临损失。 风险提示：基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但不保证基金一定盈 利，也不保证最低收益。销售机构根据法规要求对投资者类别、风险承受能力和基金的风险等级进行划 ...

Core Viewpoint - The company, Youran Dairy (09858), is engaging in a share placement and subscription agreement, with a share price set at HKD 3.92, which represents an approximate 8.84% discount from the last trading price of HKD 4.30 [1][2]. Group 1: Share Placement and Subscription Details - On January 16, 2026, the company entered into a placement and subscription agreement, where the seller will sell shares and the placement agent will facilitate the sale to at least six subscribers at a price of HKD 3.92 per share [1]. - The company will issue new shares equivalent to the number of shares sold under the placement agreement at the same price of HKD 3.92 per share [1]. - The estimated net proceeds from the subscription are expected to be approximately HKD 11.72 billion [2]. Group 2: Share Capital Impact - The placement shares will represent about 7.14% of the company's enlarged issued share capital after the completion of the subscription [2]. - The total issued share capital after the placement and subscription will be approximately 6.66% larger than before [2]. - The number of shares to be subscribed under the special authorization agreement is 299 million, which will also represent about 7.14% of the enlarged issued share capital [2].

Group 1 - Tian Sheng New Materials (300169.SZ) announced a share transfer agreement on January 14, 2026, where Rongsheng Xintai will acquire a total of 20.4895 million shares from Sun Jian and Lü Zewei at a price of 6.39 yuan per share, representing 3.47% and 2.81% of the company's total shares respectively [1][2] - Following the share transfer, Rongsheng Xintai will hold 6.29% of the company's total shares [1] - On the same day, the company signed a conditional share subscription agreement with Rongsheng Zhirui, which plans to subscribe for all 50 million shares issued by the company, resulting in a holding ratio of 13.30% post-issuance [1][2] Group 2 - As a result of these transactions, Rongsheng Zhirui will become the controlling shareholder of the listed company, with Rongsheng Xintai as a concerted actor, and the actual controller Wei Lidong will become the actual controller of the company [2] - The company’s board of directors approved a proposal for a specific object issuance of A-shares, with total fundraising not exceeding 253 million yuan, which will be used to repay bank loans and/or supplement working capital [2] - The company's stock will resume trading on January 16, 2026 [3]

Core Viewpoint - The article discusses the transfer of shares of Innovent Biologics (09939) from Futu Securities International Hong Kong to BOC International Securities, with a total market value of HKD 124 million, representing 11.04% of the shares [1] Group 1: Share Transfer and Agreement - On July 31, shareholders of Innovent Biologics transferred shares valued at HKD 124 million to BOC International Securities, accounting for 11.04% of the total shares [1] - Innovent Biologics announced an agreement with Dr. Tong Youzhi and the seller (KT International Investment Limited) to sell 20.673 million shares at a price of HKD 2.08 per share, which is approximately 4.62% of the company's issued share capital [1] Group 2: Fundraising Purpose - The placement and subscription are aimed at supplementing the long-term funding for the group's general business and growth strategy [1] - The net proceeds from the subscription are estimated to be approximately HKD 40.34 million after deducting related expenses, which will be used for general working capital and business operations [1]